PLX — Protalix BioTherapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1006281 ·
Last close
$2.70
Market Cap
$217.54M
52W High
$3.19
52W Low
$1.60
ADV30
802,854
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 19,896,000 | 12,134,000 | 4,672,000 | 3,777,000 | 110,336,000 | 27,420,000 | 38,932,000 |
| Mar 2026 | 33,750,000 | 29,623,000 | 21,146,000 | 18,317,000 | 102,336,000 | 41,001,000 | 35,107,000 |
| Dec 2025 | 9,122,000 | 4,503,000 | -4,658,000 | -5,504,000 | 82,346,000 | 14,680,000 | 34,116,000 |
| Sep 2025 | 17,851,000 | 9,527,000 | 2,131,000 | 2,355,000 | 82,264,000 | 13,647,000 | 29,356,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,090,000
Investing CF
$2,169,000
Financing CF
$4,400,000
CapEx
$-2,093,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.20
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-366,680,000
Inventory
$30,474,000
Receivables
$2,939,000
ST Investments
$10,082,000
EBIT TTM
$20,804,000
Pretax Income TTM
$19,265,000
Interest Exp TTM
$1,539,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$80,619,000
EBITDA
$24,860,000
Free Cash Flow
$2,992,375
Enterprise Value
$181,260,128
Total Cash
$40,656,000
Total Debt
$9,207,000
Shares Out
80,571,642
Trailing EPS
$0.23
Book Value
$0.83
ROE
31.2%
ROA
15.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 52,744,000 | -5,500,000 | -6,604,000 | 82,346,000 | 34,116,000 | 48,230,000 | -11,993,000 |
| Dec 2024 | 53,399,000 | 3,917,000 | 2,932,000 | 73,417,000 | 30,206,000 | 43,211,000 | 8,674,000 |
| Dec 2023 | 65,494,000 | 10,460,000 | 8,312,000 | 84,434,000 | 50,865,000 | 33,569,000 | -1,318,000 |
| Dec 2022 | 47,638,000 | -13,014,000 | -14,927,000 | 55,787,000 | 66,427,000 | -10,640,000 | -25,000,000 |
TTM Snapshot
Revenues TTM
$76,381,000
NetIncome TTM
$15,332,000
OpCashFlow TTM
—
Assets (Latest)
$102,336,000
Forward EPS
$0.62
Max Pain — expiry 2027-02-19
max pain strike: $2.50 · spot: $2.70 · call oi: 4,176 · put oi: 237
Expected Move to 2027-02-19:
±$0.95
(35.19%) —
implied range
$1.75 –
$3.65
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALEC | Alector, Inc. | $225.55M | $2.02 | — |
| IVVD | Invivyd, Inc. | $206.45M | $0.70 | — |
| CGEN | COMPUGEN LTD | $200.82M | $2.12 | — |
| ACOG | Alpha Cognition Inc. | $196.87M | $9.04 | — |
| PALI | PALISADE BIO, INC. | $252.69M | $1.45 | — |
News headlines (Yahoo Finance, 1h cache)
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
2026-09-08 10:45 · Yahoo
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
2026-08-12 23:04 · Yahoo
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-12 10:50 · Yahoo
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
2026-08-05 10:50 · Yahoo
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
2026-05-13 12:19 · Yahoo
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
2026-05-13 23:02 · Yahoo
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
2026-05-13 10:50 · Yahoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
2026-05-06 10:50 · Yahoo
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-14 02:01 · Yahoo
PLX: Elfabrio Estimates Up
2026-08-13 17:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.